Thermo Fisher Scientific (TMO) Shares Sold by US Bancorp DE

US Bancorp DE lowered its stake in shares of Thermo Fisher Scientific (NYSE:TMO) by 0.7% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 235,953 shares of the medical research company’s stock after selling 1,693 shares during the period. US Bancorp DE owned approximately 0.06% of Thermo Fisher Scientific worth $48,714,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TMO. Longview Partners Guernsey LTD boosted its position in Thermo Fisher Scientific by 6.8% in the 4th quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock valued at $926,024,000 after buying an additional 311,977 shares during the period. Geode Capital Management LLC boosted its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 3,917,221 shares of the medical research company’s stock valued at $742,108,000 after buying an additional 158,961 shares during the period. Wells Fargo & Company MN boosted its position in Thermo Fisher Scientific by 0.3% in the 1st quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock valued at $660,446,000 after buying an additional 9,820 shares during the period. Clearbridge Investments LLC boosted its position in Thermo Fisher Scientific by 5.3% in the 4th quarter. Clearbridge Investments LLC now owns 2,862,399 shares of the medical research company’s stock valued at $543,512,000 after buying an additional 143,518 shares during the period. Finally, C WorldWide Group Holding A S boosted its position in Thermo Fisher Scientific by 1.9% in the 4th quarter. C WorldWide Group Holding A S now owns 2,277,108 shares of the medical research company’s stock valued at $432,378,000 after buying an additional 43,368 shares during the period. 86.52% of the stock is owned by hedge funds and other institutional investors.

In other news, Director William G. Parrett sold 1,000 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $211.43, for a total value of $211,430.00. Following the sale, the director now directly owns 11,660 shares in the company, valued at approximately $2,465,273.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of the firm’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the completion of the sale, the chief executive officer now owns 334,622 shares in the company, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders sold a total of 43,500 shares of company stock worth $9,129,330 over the last 90 days. Company insiders own 0.49% of the company’s stock.

Shares of TMO opened at $214.94 on Friday. Thermo Fisher Scientific has a twelve month low of $170.07 and a twelve month high of $226.44. The firm has a market capitalization of $84.89 billion, a PE ratio of 21.31, a PEG ratio of 1.55 and a beta of 1.14. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The business had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period last year, the business earned $2.08 EPS. The company’s revenue was up 22.8% on a year-over-year basis. equities analysts expect that Thermo Fisher Scientific will post 10.91 EPS for the current year.

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, March 26th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Barclays raised their price target on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, Bank of America raised their price target on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $224.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply